Last reviewed · How we verify
OXYCONTIN®
OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain.
OxyContin is a prescription medication developed by Mundipharma (China) Pharmaceutical Co. Ltd, but its target, drug class, and approved indications are unknown. As a small molecule, its exact mechanism of action is unclear. OxyContin's commercial status, including patent status and generic availability, is also unknown. Key safety considerations are not specified. Further research is needed to understand this medication's properties and uses.
At a glance
| Generic name | OXYCONTIN® |
|---|---|
| Also known as | OXYCONTIN® Tablet 10 mg, OxyContin 40 mg Extended-Release Tablet, OXYCONTIN® Tablet 40 mg |
| Sponsor | Mundipharma (China) Pharmaceutical Co. Ltd |
| Target | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Imagine your brain has special locks that control how much pain you feel. OxyContin is a key that fits into these locks, making it harder for pain signals to get through. This can help reduce the amount of pain you feel, but it can also have side effects and risks.
Approved indications
- Acute postoperative pain
- Chronic Pain with Opioid Tolerance
- Severe pain
Common side effects
- Constipation
- Nausea
- Somnolence
- Dizziness
- Vomiting
- Pruritus
- Headache
- Dry mouth
- Asthenia
- Sweating
- Abdominal pain
- Diarrhea
Serious adverse events
- Respiratory depression
- Apnea
- Respiratory arrest
- Circulatory depression
- Hypotension
- Shock
- Withdrawal syndrome with seizures
- Hallucination
- Syncope
- Urinary retention
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (NA)
- 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (PHASE2)
- Buprenorphine-Fentanyl Interaction Study (PHASE1)
- Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction (PHASE3)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex (PHASE2,PHASE3)
- Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXYCONTIN® CI brief — competitive landscape report
- OXYCONTIN® updates RSS · CI watch RSS
- Mundipharma (China) Pharmaceutical Co. Ltd portfolio CI